The standard treatment for patients with advanced non-small cell lung cancer is a combination of two old-fashioned cytotoxic chemotherapy drugs. The combination, however, comes with substantial toxicity. Now researchers report that a combination of two molecularly targeted agents may provide similar therapeutic benefit with less toxicity.